Navigation Links
Heart Failure Patient Supported By DuraHeart™ Left-Ventricular Assist System Receives Successful Donor Transplant After Four Years On Device
Date:12/22/2009

rnal components of the DuraHeart became a natural extension of my body, allowing me to do most everything and go anywhere. I truly appreciate the second chance that this life-sustaining technology provided to me until a suitable donor heart became available.”

“We are grateful for the contribution we are making to the treatment of heart failure patients,” said William Pinon, President and CEO, Terumo Heart. “This is a significant milestone that further documents the importance and value of LVAS technology for its potential to improve the length and quality of patients’ lives.”

The DuraHeart LVAS is the first, third-generation rotary pump designed for long-term patient support that incorporates a centrifugal flow rotary pump with an active magnetically levitated impeller featuring three position sensors and magnetic coils that optimize blood flow, while minimizing device wear and tear. The DuraHeart LVAS is currently being studied in the U.S. in the DuraHeart Pivotal Trial for Bridge-to-Transplant, a multi-center, prospective, non-randomized study, involving 140 patients. The study will evaluate the safety and efficacy of the device in helping to sustain patients awaiting heart transplant who are at risk of death due to end-stage left ventricular failure. The DuraHeart LVAS carries a CE Mark and is currently available for sale in European countries. Additionally, the company has completed clinical trial enrollment for this device in Japan.

About Heart Failure
More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization. The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transplants annually, but less than 3,000 will rece
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5

Related medicine news :

1. Breast-Feeding May Protect a Womans Heart
2. Heartland Health Named 2009 Baldrige Award Recipient
3. Half-Million Doctors Beg Senate to Kill the Bill - Virtual News Conference by Coalition of More Than 40 Medical Groups Sunday, 2 pm EST; Sweetheart Deals Punish Patients in Other States
4. Natural Heart Drugs May Combat Colon Cancer
5. Disparity in use of implantable devices to prevent sudden death in heart failure patients
6. Facing the Holidays with a Heavy Heart: Four Ways to Show You Care During a Darker Christmas Season
7. Obesity, Inactivity Keeping Heart Health Stats Down
8. Low cholesterol transfer protein activity associated with heart disease risk
9. Normal Cholesterol Doesnt Guarantee Healthy Heart
10. Contributors to Heart Failure Identified
11. Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Heart Failure Patient Supported By DuraHeart™ Left-Ventricular Assist System Receives Successful Donor Transplant After Four Years On Device   
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has ... the company’s chief executive officer has announced a new promotion ... offered at discounted prices, from 15 to 26 percent off. ... in huge demand in the current market. We are excited ... a lot of high quality products for sale. Many of ...
(Date:7/13/2014)... 13, 2014 Micro irrigation systems are ... water dispersal as wells as to maintain soil quality. ... projected to become a dominant revenue generator for manufacturers ... to reduce resource costs has led to the adoption ... and has further caused massive demand for micro irrigation ...
(Date:7/13/2014)... Fuel additives are chemicals, which are added ... kerosene, and so on, in order to enhance their ... corrosion effects caused by fuels and improving the combustion ... provide economies of scale in the long run, but, ... of the fuel products. , The various fuel additive ...
(Date:7/13/2014)... 2014 A Massachusetts couple who have ... risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... federal regulators, as they presented poignant testimony on the ... Administration (FDA) advisory panel meeting convened to address the ... Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and his ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
Breaking Medicine News(10 mins):Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... Asia are born and die without leaving a trace ... information on which to base public health decisions, a ... colleagues say in a paper published today (Oct. 29, ... However, affordable solutions exist to collect these vital statistics ...
... Treatment Times, Optimize Planning, Objectives and Offer Increased ... Oct. 29 Accuray,Incorporated (Nasdaq: ARAY ), ... today four new products designed to improve treatment ... in radiation delivery. These products are being launched ...
... Ongoing Oncology Program for MDX-1106, PRINCETON, N.J., ... Inc. (Nasdaq: MEDX ) announced today the ... with the U.S. Food &,Drug Administration (FDA) for ... a fully human anti-PD-1 antibody being,investigated for the ...
... SAN DIEGO, Oct. 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... to,present at the BIOCOM Investor Conference on November 2, ... at the Marriott Del Mar Hotel in San,Diego, California. ... to provide a corporate overview of the company and,its ...
... Office of Technology and Intellectual Property, has received a ... Society of U.S.A. and Canada. , The award stems ... University of Chicago and the Mayo Clinic. The deal ... risk of side effects from a standard first-line treatment ...
... S.C., Oct. 29 The federal government has,approved ... Medicare,Advantage and Medicare Part D product offerings. Enrollment ... BlueCross, products include two PPO plans, Medicare Blue(SM) ... Blue(SM),Private; and two prescription drug plans, MedBlue(SM) Rx ...
Cached Medicine News:Health News:Scandal of invisibility plagues countries with no civil registries 2Health News:Scandal of invisibility plagues countries with no civil registries 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 2Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 4Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 5Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 3Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 4Health News:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 2Health News:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 3Health News:Gene screen patent leads to 'Deal of Distinction' 2
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
... Scientific Sessions ... 2007 in Orlando, Florida, ... ) today announced the successful completion,of its Phase 2b trial ... vaccine being,developed to treat nicotine addiction and prevent smoking relapse. ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: